ASH Annual Meeting & Exposition: DLBCL

Videos

An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.

Armin Ghobadi, MD, on Recent Advancements in the Treatment of Patients with DLBCL

Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Armin Ghobadi, MD, Discusses Trials Needed to Build on Blinatumomab Pilot Study Data

Ghobadi explained an interesting correlation found in the results of his study presented at the 2020 ASH Annual Meeting & Exposition.

Ghobadi on the Correlation Between CD8/CD4 Ratio and Responses to Blinatumomab in Patients With DLBCL

The ongoing GO29365 study of combination regimens containing polatuzumab vedotin (Polivy) for patients with relapsed or refractory diffuse large B-cell lymphoma added an additional 106 patients to confirm preliminary findings of safety and efficacy.

Laurie H. Sehn, MD, MPH, Discusses the Extension Arm of the Phase 2 GO29365 Trial in DLBCL

Articles

A recent study found a difference in preference when it came to the administration of rituximab in patients with blood cancer. 

Study Finds Nurses Prefer IV Rituximab Administration in DLBCL Treatment 

Research from a pilot trial presented at the 2020 American Society of Hematology (ASH) Annual Meeting found above average complete response and disease-free survival rates for patients with DLBCL.

Armin Ghobadi, MD, on Blinatumomab Consolidation Post Stem-Cell Transplant for DLBCL

The preliminary findings of the extension arm of the phase 2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin (Polivy) plus bendamustine (Bendeka) and rituximab (Rituxan) for patients with diffuse large B cell lymphoma.

Laurie H. Sehn, MD, Discusses Preliminary Findings From the GO29365 Study in DLBCL

Research presented at the 2020 ASH Annual Meeting may have found an alternative path forward for patients who do not respond to immunotherapy treatment for large B-cell lymphomas.

Engineering Novel CAR T-Cells to Overcome CD58 Loss Alternative for Immunotherapy-Resistant Patients with Large B-Cell Lymphomas

A novel ROR1-targeted antibody-drug conjugate, VLS-101, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.

Novel ADC Shows Clinical Activity in MCL and DLBCL, First-in-Human Trial Finds

The CAR T-cell therapy axicabtagene ciloleucel demonstrated long-term disease control with rapid responses and robust CAR T-cell expansion among patients with refractory large B-cell lymphoma.

ASH Annual Meeting & Exposition: DLBCL | Conference